LIQUID-GUIDED ACOUSTIC WAVE IMMUNOSENSOR

BIODE, INC., WILL UTILIZE THE RESULTS OF ITS PHASE I RESEARCH TO DEVELOP A TOTALLY NEW SOLID-STATE BIOSENSOR TECHNOLOGY FOR BIOLOGICAL MEASUREMENTS. THIS TECHNOLOGY IS BASED UPON THE MERGING OF TWO OTHER RELATIVELY NEW TECHNOLOGIES, MONOCLONAL ANTIBODIES (HYBRIDOMA TECHNOLOGY) WITH ACOUSTIC WAVE MICROSENSORS. BY COMBINING THE SENSITIVITY OF ACOUSTIC WAVE SENSORS WITH THE SPECIFICITY OFANTIBODIES, BIODE, INC., WILL CREATE A NOVEL DETECTION TECHNOLOGY WITH THE POTENTIAL TO OVERCOME THE DRAWBACKS OF EXISTING IMMUNOASSAY TECHNOLOGY. THIS NEW IMMUNOSENSOR WILLOPERATE IN A CONTINUOUS AND THEREFORE HOMOGENEOUS MODE, YET IT IS EXPECTED TO EQUAL OR EXCEED THE SENSITIVITY LIMITS OF EXISTING HETEROGENEOUS IMMUNOASSAYS. AN ACOUSTIC WAVE MICROSENSOR BASED UPON THE PRINCIPLE OF LIQUID-GUIDED ACOUSTIC WAVE (LGAW) TECHNOLOGY WILL BE TESTED. THE IMMUNOSENSOR TECHNOLOGY WILL ALLOW FOR HOMOGENEOUS ASSAYS THAT MEET OR EXCEED THE PRESENT STATE-OF-THE-ART HETEROGENEOUS ASSAYS. AS THE LGAW IMMUNOSENSOR TECHNOLOGY PROPOSED BY BIODE, INC., DOES NOT NOW EXIST, IT REPRESENTS A TRUE TECHNOLOGICAL INNOVATION SHOULD THE FEASIBILITY RESULTS OF PHASE I RESEARCH PROVE FRUITFUL.